{
  "name": "Infant Bacterial Therapeutics",
  "slug": "infant-bacterial-therapeutics",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T04:15:59Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 65.90, volym 4374",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/infant-bacterial-therapeutics/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-06",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b027354d8e44a5d55bc4685ce60a31680&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aab98738e2c5e633c3f51d1ff0cf52426",
            "date": "2026-05-06",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "IBT_Delarsrapport_Q1_2026_SWE.pdf",
            "text_chars": 25715,
            "sha256": "60547f958272dd40ba2712e07317218b73088891e55b691618e32cfdcb697788",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 25715
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-27",
        "title": "Årsredovisning 2025",
        "original_title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb79125e01308503d8fb0682efb0e64c0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8c22c84d7301089482c83358d64784a4",
            "date": "2026-03-27",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "IBT_AR_2025_SWE.pdf",
            "text_chars": 126960,
            "sha256": "57d5849913dcb69ecf4754806e59c338a346dfc9a40e3c06e522c8255e4d9c1a",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 126960
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-06",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b000eddc922590847a6e3ee0d56221b3f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a66490c3b1577450316a0e9ff1c7f1af0",
            "date": "2026-02-06",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "IBT_Bokslutskommunike_Q4_2025_SWE.pdf",
            "text_chars": 23017,
            "sha256": "f0075fd94502b2a6d54a9ec3f7ad5ee50db8f09da508060f5cb663e1959987e9",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 23017
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-13",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bc6cede42db1d7a976b2e88e76bbfd15a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a917c68d40817e6683d3ddbe39cc8ede0",
            "date": "2025-11-13",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "IBT_Delarsrapport_Q3_2025_SWE.pdf",
            "text_chars": 28703,
            "sha256": "eff505bc2ee8be453261fe103f9076d941f5b9abd186965a5e2d4bdc2dac5505",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 28703
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-20",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3b6d7c8e695faa8f16d807ea4db5b340&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a1b435d92c4f4ae2608ff1bc2cd7539a3",
            "date": "2025-08-20",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "IBT_Delarsrapport_Q2_2025_SWE.pdf",
            "text_chars": 29386,
            "sha256": "cb1be1894b069461b3f76ae27243aa2c1e06a97909be21597672f49f865e7cbd",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 29386
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-07",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7812a17f37d874ba0372929cb127d527&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a697a551aa54bc2748df37c10092bee28",
            "date": "2025-05-07",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "IBT_Delarsrapport_Q1_2025_SWE.pdf",
            "text_chars": 23394,
            "sha256": "254e2c7f46096af3ba99a4b04ad8190770155a87929019b5f91f29ad23f09e0e",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 23394
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-03-27",
        "title": "Årsredovisning 2024",
        "original_title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bdada50e058b5762e4fb9f8442f6ecf8a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6f888496f180b76dd578e4bec19c9ca5",
            "date": "2025-03-27",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "IBT_AR_2024_SWE.pdf",
            "text_chars": 128182,
            "sha256": "e8ac50795bc8b094a5d257f04dfc2fd0ebaaa24f3678d4f1bf48188dc98dccbc",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 128182
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-13",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Bokslutskommuniké 1 januari - 31 december 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b219653b47b21d8d37022e6efc14f4497&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a75ff970d41a7f900c40093f0e44f40ca",
            "date": "2025-02-13",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "IBT_Bokslutskommunike_2024_SWE.pdf",
            "text_chars": 28388,
            "sha256": "60673f59815137502ce0484f4dff8728d5b74a7739ce3cc53291776654892714",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 28388
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-14",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 30 september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be2a184557531627f12b4c743e4162be9&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac8f2b73a9b8bf06d95baa057ee338fc3",
            "date": "2024-11-14",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "IBT_Q3_2024_SWE.pdf",
            "text_chars": 31917,
            "sha256": "8fa6fb15345a38a89d633e003181c4d9316286be92b6fe92e2ee91ea19dfdb52",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 31917
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-28",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 juni 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b879b094182889bce0984b3e5d04e5f11&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a0cc900329bea0b4d50080bd6355bda22",
            "date": "2024-08-28",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "IBT_Q2_2024_SWE.pdf",
            "text_chars": 30065,
            "sha256": "828207bdc489450224f095a0e200679a215d28b9d73bdc3f17a46a77068ee59b",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 30065
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-07",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Infant Bacterial Therapeutics AB (publ) Delårsrapport 1 januari - 31 mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7d0f45700fa593a9e0b100e952ba66f4&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af20d6c8b8ab9d41a8631f94b247f5b51",
            "date": "2024-05-07",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "IBT_Q1_2024_SWE.pdf",
            "text_chars": 27735,
            "sha256": "6ed837bdc6bdb7a412198cd615dc48f759cf9381b4e368d1d10d666e84a49bc1",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 27735
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-25",
        "title": "Årsredovisning 2023",
        "original_title": "Infant Bacterial Therapeutics AB publicerar Årsredovisning för räkenskapsåret 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=ba67f73ce2150c6f2b071c09711935ca8&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a83118a0ffca658a51b7661b06f9d367b",
            "date": "2024-03-25",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "IBT_Arsredovisning_2023.pdf",
            "text_chars": 143392,
            "sha256": "e0e4c6cdf0708d6b045abc77f70fe01082123b17c52426cdd1cd9b385347ca0c",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 143392
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-08",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Infant Bacterial Therapeutics AB (publ), Bokslutskommuniké 1 januari - 31 December 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2c256b9cecd4622a19b3fb7f0696c6e7&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a32e4c171dc57857ab695a042d279a1ad",
            "date": "2024-02-08",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "IBT_Bokslutskommumike_2023_SWE.pdf",
            "text_chars": 36086,
            "sha256": "0d62610a160ae9194d24a678fc256c4156241f31155955b7ddd6ebee83312994",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 36086
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-10",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 September 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7670857707eac3635c8c61428b078d49&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/acbf891c15f9e41312f319d0ddc1594b3",
            "date": "2023-11-10",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "IBT_Q3_2023_SWE.pdf",
            "text_chars": 39437,
            "sha256": "f05f5d227315ed3ee516f2036ecf70a3ffbd03bf221bb18effe2dd19f6987e40",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 39437
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-25",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 30 juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b40d0cf9c5bfd2045fc4f738fb5be832e&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ab00cd4908db4148bfe82b553f3543eba",
            "date": "2023-08-25",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "IBT_Q2_2023_SWE.pdf",
            "text_chars": 35246,
            "sha256": "4dfb488ba5020d824c3e34b05c4e7f98e2e5239bdfc522ec7c0276ecec505a8a",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 35246
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-08",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Infant Bacterial Therapeutics AB (publ), Delårsrapport 1 januari - 31 mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf428a2811566892e1897cbddae12e0ec&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae1ad6598b6277e4600d2810e334d2c8f",
            "date": "2023-05-08",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "IBT_Q1_2023_SWE.pdf",
            "text_chars": 28232,
            "sha256": "ab30a5ae58ec8f12c3625d739c21cd62e25f33078af1b4aba15c0931ed6806bc",
            "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 28232
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Infant Bacterial Therapeutics",
    "identity": {
      "issuer": "INFANT BACTERIAL THERAPEUTICS AB",
      "lei": "2138008KVBXCRJGP6Z26",
      "source": "FI insynsregister",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Infant Bacterial Therapeutics",
      "query": "INFANT BACTERIAL THERAPEUTICS AB",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T04:15:59Z",
    "insider": {
      "transactions": 13,
      "all_export_rows": 13,
      "acquisitions": 10,
      "disposals": 0,
      "other": 3,
      "acquisition_value_sek": 475433.6,
      "disposal_value_sek": 0,
      "characters": {
        "Förvärv": 10,
        "Tilldelning": 3
      }
    },
    "short_selling": {
      "aggregate_percent": null,
      "current_public_positions": 0,
      "historical_changes": 0,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX2023390",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/ibt-b?id=TX2023390"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Infant Bacterial Therapeutics",
      "expected_name": "Infant Bacterial Therapeutics",
      "match_score": 100.0,
      "slug": "infant-bacterial-therapeutics",
      "url": "https://mfn.se/all/a/infant-bacterial-therapeutics",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://ibtherapeutics.com/"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX2023390",
      "asset_class": "SHARES",
      "isin": "SE0008015259",
      "symbol": "IBT B",
      "company": "Infant Bacterial TherapeuticsB",
      "market": null,
      "last_sale_price": "SEK 65.90",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "INFANT BACTERIAL THERAPEUTICS AB",
      "lei": "2138008KVBXCRJGP6Z26",
      "source": "FI insynsregister",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Infant Bacterial Therapeutics",
      "query": "INFANT BACTERIAL THERAPEUTICS AB",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aab98738e2c5e633c3f51d1ff0cf52426",
      "date": "2026-05-06",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "IBT_Delarsrapport_Q1_2026_SWE.pdf",
      "text_chars": 25715,
      "sha256": "60547f958272dd40ba2712e07317218b73088891e55b691618e32cfdcb697788",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 25715
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8c22c84d7301089482c83358d64784a4",
      "date": "2026-03-27",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "IBT_AR_2025_SWE.pdf",
      "text_chars": 126960,
      "sha256": "57d5849913dcb69ecf4754806e59c338a346dfc9a40e3c06e522c8255e4d9c1a",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 126960
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a66490c3b1577450316a0e9ff1c7f1af0",
      "date": "2026-02-06",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "IBT_Bokslutskommunike_Q4_2025_SWE.pdf",
      "text_chars": 23017,
      "sha256": "f0075fd94502b2a6d54a9ec3f7ad5ee50db8f09da508060f5cb663e1959987e9",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 23017
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a917c68d40817e6683d3ddbe39cc8ede0",
      "date": "2025-11-13",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "IBT_Delarsrapport_Q3_2025_SWE.pdf",
      "text_chars": 28703,
      "sha256": "eff505bc2ee8be453261fe103f9076d941f5b9abd186965a5e2d4bdc2dac5505",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 28703
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a1b435d92c4f4ae2608ff1bc2cd7539a3",
      "date": "2025-08-20",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "IBT_Delarsrapport_Q2_2025_SWE.pdf",
      "text_chars": 29386,
      "sha256": "cb1be1894b069461b3f76ae27243aa2c1e06a97909be21597672f49f865e7cbd",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 29386
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a697a551aa54bc2748df37c10092bee28",
      "date": "2025-05-07",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "IBT_Delarsrapport_Q1_2025_SWE.pdf",
      "text_chars": 23394,
      "sha256": "254e2c7f46096af3ba99a4b04ad8190770155a87929019b5f91f29ad23f09e0e",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 23394
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6f888496f180b76dd578e4bec19c9ca5",
      "date": "2025-03-27",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "IBT_AR_2024_SWE.pdf",
      "text_chars": 128182,
      "sha256": "e8ac50795bc8b094a5d257f04dfc2fd0ebaaa24f3678d4f1bf48188dc98dccbc",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 128182
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a75ff970d41a7f900c40093f0e44f40ca",
      "date": "2025-02-13",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "IBT_Bokslutskommunike_2024_SWE.pdf",
      "text_chars": 28388,
      "sha256": "60673f59815137502ce0484f4dff8728d5b74a7739ce3cc53291776654892714",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 28388
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac8f2b73a9b8bf06d95baa057ee338fc3",
      "date": "2024-11-14",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "IBT_Q3_2024_SWE.pdf",
      "text_chars": 31917,
      "sha256": "8fa6fb15345a38a89d633e003181c4d9316286be92b6fe92e2ee91ea19dfdb52",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 31917
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a0cc900329bea0b4d50080bd6355bda22",
      "date": "2024-08-28",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "IBT_Q2_2024_SWE.pdf",
      "text_chars": 30065,
      "sha256": "828207bdc489450224f095a0e200679a215d28b9d73bdc3f17a46a77068ee59b",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 30065
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af20d6c8b8ab9d41a8631f94b247f5b51",
      "date": "2024-05-07",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "IBT_Q1_2024_SWE.pdf",
      "text_chars": 27735,
      "sha256": "6ed837bdc6bdb7a412198cd615dc48f759cf9381b4e368d1d10d666e84a49bc1",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 27735
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a83118a0ffca658a51b7661b06f9d367b",
      "date": "2024-03-25",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "IBT_Arsredovisning_2023.pdf",
      "text_chars": 143392,
      "sha256": "e0e4c6cdf0708d6b045abc77f70fe01082123b17c52426cdd1cd9b385347ca0c",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 143392
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a32e4c171dc57857ab695a042d279a1ad",
      "date": "2024-02-08",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "IBT_Bokslutskommumike_2023_SWE.pdf",
      "text_chars": 36086,
      "sha256": "0d62610a160ae9194d24a678fc256c4156241f31155955b7ddd6ebee83312994",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 36086
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/acbf891c15f9e41312f319d0ddc1594b3",
      "date": "2023-11-10",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "IBT_Q3_2023_SWE.pdf",
      "text_chars": 39437,
      "sha256": "f05f5d227315ed3ee516f2036ecf70a3ffbd03bf221bb18effe2dd19f6987e40",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 39437
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ab00cd4908db4148bfe82b553f3543eba",
      "date": "2023-08-25",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "IBT_Q2_2023_SWE.pdf",
      "text_chars": 35246,
      "sha256": "4dfb488ba5020d824c3e34b05c4e7f98e2e5239bdfc522ec7c0276ecec505a8a",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 35246
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae1ad6598b6277e4600d2810e334d2c8f",
      "date": "2023-05-08",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "IBT_Q1_2023_SWE.pdf",
      "text_chars": 28232,
      "sha256": "ab30a5ae58ec8f12c3625d739c21cd62e25f33078af1b4aba15c0931ed6806bc",
      "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 28232
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/infant-bacterial-therapeutics",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12936,
      "sha256": "b2dfe019cedecef56729e8f0e043bac03afdb398358b1e767744140ecc5c3243",
      "url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/infant-bacterial-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12936
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/infant-bacterial-therapeutics/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/infant-bacterial-therapeutics/market/history.json",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/infant-bacterial-therapeutics/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/infant-bacterial-therapeutics/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/infant-bacterial-therapeutics/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/infant-bacterial-therapeutics/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/infant-bacterial-therapeutics/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/infant-bacterial-therapeutics/finansinspektionen",
    "transaction_count": 13,
    "aggregate_short_percent": null,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/infant-bacterial-therapeutics/llms.txt",
  "json_url": "/company/infant-bacterial-therapeutics/company.json",
  "document_index_url": "/company/infant-bacterial-therapeutics/documents.json",
  "absolute_url": "https://spela.port0.org/company/infant-bacterial-therapeutics"
}